Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315848 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
A Phase 3 study of Osteoarthritis, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 10
- Study locations
NCT00315848: Completed Phase 3 study of Osteoarthritis, sponsored by Purdue Pharma.
NCT00315848 is a Phase 3 study of Osteoarthritis that has completed, run by Purdue Pharma. The registered enrollment target is 225 participants, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (72% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00315848, a Phase 3 study of Osteoarthritis, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 10
- Study locations
Study Summary
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and immediate release oxycodone/acetaminophen in subjects with osteoarthritis pain inadequately treated with non-opioid analgesics. The double-blind treatment intervention duration is 60 days.
Conditions Studied
Interventions
- DRUG Buprenorphine transdermal delivery system
Study Locations (10)
Arizona
- Arizona Research and Education - Phoenix
- Phoenix Center for Clinical Research - Phoenix
Florida
- Gainesville Clinical Research Center - Gainesville
- Park Place Therapeutic Center - Plantation
Texas
- Metroplex Clinical Research Center - Dallas
- Arthritis Diagnostic and Treatment Center - San Antonio
Alabama
- Rheumatology Associates of North Alabama - Huntsville
Colorado
- Western Integrated Pain Treatment Centers - Westminster
Indiana
- MediSphere Medical Research Center, L.L.C. - Evansville
New York
- Stratton VA Medical Center - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 1996-11 |
| Est. Completion | 1999-12 |
| Phase | Phase 3 |
What the finished NCT00315848 record still lists
NCT00315848 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine transdermal delivery system is the first listed.
NCT00315848 lists 10 locations in 7 states (Arizona, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT00315848 about?
NCT00315848 is a clinical study titled "The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.". The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and immediate release oxycodone/acetaminophen in subjects with osteoarthritis pain inadequately treated with non-opi...
What is the current status of trial NCT00315848?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 1996-11. Estimated completion is 1999-12.
What conditions does trial NCT00315848 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT00315848?
The interventions under investigation include: Buprenorphine transdermal delivery system (DRUG).
Who is sponsoring clinical trial NCT00315848?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315848 being conducted?
This trial has 10 study locations across Alabama, Arizona, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00315848's enrollment target sits among peer trials
225 52nd of 135 higher than 84 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Beat Pain Better Trial
RECRUITING · Phase 3
-
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
RECRUITING · Phase 3
-
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
COMPLETED · Phase 3
-
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
COMPLETED · Phase 3
-
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia